Table 1.

Correlation of sAxl serum levels with various clinicopathological parameters

		sAxl
Variable	Number of cases	High	Low	OR	CI 95%	P
Age (years)
<55	162	73 (45.1%)	89 (54.9%)	1.497	0.939–2.388	0.098
≥55	127	70 (55.1%)	57 (44.9%)
Gender
Male	256	125 (48.8%)	131 (51.2%)	1.354	0.753–2.434	0.373
Female	55	31 (56.4%)	24 (43.6%)
HBV status
Negative	33	13 (39.4%)	20 (60.6%)	1.578	0.750–3.318	0.267
Positive	237	120 (50.6%)	117 (49.4%)
HCV status
Negative	275	137 (49.8%)	138 (50.2%)	0.863	0.283–2.635	1.000
Positive	13	6 (46.2%)	7 (53.8%)
Cirrhosis
No	53	18 (34.0%)	35 (66.0%)	1.734	0.906–3.318	0.110
Yes	157	74 (47.1%)	83 (52.9%)
Vascular invasion
No	145	60 (41.4%)	85 (58.6%)	1.728	1.018–2.932	0.045
Yes	91	50 (54.9%)	41 (45.1%)
Lymph node metastasis
No	256	116 (45.3%)	140 (54.7%)	2.897	1.511–5.552	0.001
Yes	51	36 (70.6%)	15 (29.4%)

CI, confidence interval; OR, odds ratio; HBV, hepatitis B virus; HCV, hepatitis C virus.

low sAxl < 18.575 ng/mL < high sAxl.